Literature DB >> 19846583

Unilateral pedunculopontine stimulation improves falls in Parkinson's disease.

Elena Moro1, Clement Hamani, Yu-Yan Poon, Thamar Al-Khairallah, Jonathan O Dostrovsky, William D Hutchison, Andres M Lozano.   

Abstract

Postural instability and falls are a major source of disability in patients with advanced Parkinson's disease. These problems are currently not well addressed by either pharmacotherapy nor by subthalamic nucleus deep-brain stimulation surgery. The neuroanatomical substrates of posture and gait are poorly understood but a number of important observations suggest a major role for the pedunculopontine nucleus and adjacent areas in the brainstem. We conducted a double-blinded evaluation of unilateral pedunculopontine nucleus deep-brain stimulation in a pilot study in six advanced Parkinson's disease patients with significant gait and postural abnormalities. There was no significant difference in the double-blinded on versus off stimulation Unified Parkinson's Disease Rating Scale motor scores after 3 or 12 months of continuous stimulation and no improvements in the Unified Parkinson's Disease Rating Scale part III scores compared to baseline. In contrast, patients reported a significant reduction in falls in the on and off medication states both at 3 and 12 months after pedunculopontine nucleus deep-brain stimulation as captured in the Unified Parkinson's Disease Rating Scale part II scores. Our results suggest that pedunculopontine nucleus deep-brain stimulation may be effective in preventing falls in patients with advanced Parkinson's disease but that further evaluation of this procedure is required.

Entities:  

Mesh:

Year:  2009        PMID: 19846583     DOI: 10.1093/brain/awp261

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  142 in total

1.  Combined pedunculopontine-subthalamic stimulation in Parkinson disease.

Authors:  S Khan; S S Gill; L Mooney; P White; A Whone; D J Brooks; N Pavese
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

Review 2.  Recent advances in the diagnosis and treatment of balance disorders.

Authors:  Klaus Jahn; Marianne Dieterich
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

Review 3.  The neurobiology of falls.

Authors:  Alfonso Fasano; Meir Plotnik; Francesco Bove; Alfredo Berardelli
Journal:  Neurol Sci       Date:  2012-06-05       Impact factor: 3.307

4.  Stuck in a rut: rethinking depression and its treatment.

Authors:  Paul E Holtzheimer; Helen S Mayberg
Journal:  Trends Neurosci       Date:  2010-11-08       Impact factor: 13.837

Review 5.  The pedunculopontine nucleus as a target for deep brain stimulation.

Authors:  Clement Hamani; Elena Moro; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2010-12-31       Impact factor: 3.575

6.  Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.

Authors:  Joanna L Elson; Rafael Kochaj; Richard Reynolds; Ilse S Pienaar
Journal:  Neurotox Res       Date:  2017-12-07       Impact factor: 3.911

7.  Improvement of pisa syndrome with contralateral pedunculopontine stimulation.

Authors:  Ludy C Shih; Veronique G Vanderhorst; Andres M Lozano; Clement Hamani; Elena Moro
Journal:  Mov Disord       Date:  2013-02-06       Impact factor: 10.338

8.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01

Review 9.  Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality?

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

10.  The integrative role of the pedunculopontine nucleus in human gait.

Authors:  Brian Lau; Marie-Laure Welter; Hayat Belaid; Sara Fernandez Vidal; Eric Bardinet; David Grabli; Carine Karachi
Journal:  Brain       Date:  2015-03-12       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.